Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Visit old site
Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 199

    Article Cited by others


Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus

Kaushal Shaveta, Singh Harmanjit, Thangaraju Pugazhenthan, Singh Jasbir

Year : 2014| Volume: 6| Issue : 3 | Page no: 107-113

   This article has been cited by
1 Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study
Sangeeta R. Kashyap,Karim Kheniser,Ali Aminian,Philip Schauer,Carel Le Roux,Bartolome Burguera
Obesity Science & Practice. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach
Ozal Mutlu,Osman Mutluhan Ugurel,Emrah Sariyer,Oguz Ata,Tugba Gul Inci,Erennur Ugurel,Sinem Kocer,Dilek Turgut-Balik
Journal of Biomolecular Structure and Dynamics. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
3 Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi,Amit Kumar Nayak,Anindita Behera
Biomedicine & Pharmacotherapy. 2020; 131: 110708
[Pubmed]  [Google Scholar] [DOI]
4 Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export
Fawzi Alogaili,Sivaprakasam Chinnarasu,Anja Jaeschke,Evangelia G. Kranias,David Y. Hui
Journal of Biological Chemistry. 2020; 295(14): 4631
[Pubmed]  [Google Scholar] [DOI]
5 Study on glycaemic control by canagliflozin and its effect on insulin resistance and plasma ketone in type 2 diabetes mellitus patients
JS Kumar,K Karthickeyan,BansiR Patel,KI Haroon Meeran,G Karishma,VishnuT Raveendran
Journal of Diabetology. 2019; 10(2): 83
[Pubmed]  [Google Scholar] [DOI]
6 Efficacy and safety of canagliflozin in kidney transplant patients
Mita Shah,Zaheer Virani,Prashant Rajput,Bharat Shah
Indian Journal of Nephrology. 2019; 0(0): 0
[Pubmed]  [Google Scholar] [DOI]
7 The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
Bruna de Souza Faustino,Alberto dos Reis Costa Junior,L.N.M. Bortolon,L.B.P.C. de Sá,D.R.T.W. Rocha,Alberto Krayyem Arbex
Open Journal of Endocrine and Metabolic Diseases. 2016; 06(01): 87
[Pubmed]  [Google Scholar] [DOI]
8 Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials
Rizwana Parveen,Nidhi Bharal Agarwal,Neelam Kaushal,Ghanshyam Mali,Sheikh Raisuddin
Expert Opinion on Pharmacotherapy. 2016; 17(1): 105
[Pubmed]  [Google Scholar] [DOI]
9 Berberine enhances antidiabetic effects and attenuates untoward effects of canagliflozin in streptozotocin-induced diabetic mice
Chinese Journal of Natural Medicines. 2016; 14(7): 518
[Pubmed]  [Google Scholar] [DOI]
10 Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials
Qi Meng,Yun Shen,Dajin Liu,Fei Jiang
Journal of Diabetes Investigation. 2015; : n/a
[Pubmed]  [Google Scholar] [DOI]
11 Antidiabetic Therapy in End-Stage Renal Disease
Suzanne M. Boyle,Barbara Simon,Sidney M. Kobrin
Seminars in Dialysis. 2015; 28(4): 337
[Pubmed]  [Google Scholar] [DOI]
12 Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers
Shuji Kinoshita,Kazuoki Kondo
Expert Opinion on Drug Metabolism & Toxicology. 2015; 11(1): 7
[Pubmed]  [Google Scholar] [DOI]
13 Adverse effects and safety of SGLT-2 inhibitors
S. Halimi,B. Vergès
Diabetes & Metabolism. 2014; 40(6): S28
[Pubmed]  [Google Scholar] [DOI]


Read this article